首页 > 最新文献

Journal of Laboratory and Clinical Medicine最新文献

英文 中文
Characterization and gene transfer in mesenchymal stem cells derived from human umbilical-cord blood 人脐带血间充质干细胞的特性和基因转移
Pub Date : 2005-11-01 DOI: 10.1016/j.lab.2005.07.003
Fei-Zhou Lu , Masayuki Fujino , Yusuke Kitazawa , Taro Uyama , Yuko Hara , Naoko Funeshima , Jian-Yuan Jiang , Akihiro Umezawa , Xiao-Kang Li

It has been shown that the stromal-cell population found in bone marrow can be expanded and differentiated into cells with the phenotypes of bone, cartilage, muscle, neural, and fat cells. However, whether mesenchymal stem cells (MSCs) are present in human umbilical-cord blood (UCB) has been the subject of ongoing debate. In this study, we report on a population of fibroblastlike cells derived from the mononuclear fraction of human UCB with osteogenic and adipogenic potential, as well as the presence of a subset of cells that have been maintained in continuous culture for more than 6 months. These cells were found to express CD29, CD44, CD90, CD95, CD105, CD166, and MHC class, but not CD14, CD34, CD40, CD45, CD80, CD86, CD117, CD152, or MHC class II. We also compared gene expression after gene transfer using lenti- and adenoviral vectors carrying the green fluorescence protein to the MSCs derived from UCB because a reliable gene-delivery system is required to transfer target genes into MSCs, which have attracted attention as potential platforms for the systemic delivery of therapeutic genes. The lentiviral vectors can transduce these cells more efficiently than can adenoviral vectors, and we maintained transgene expression for at least 5 weeks. This is the first report showing that UCB-derived MSCs can express exogenous genes by way of a lentivirus vector. These results demonstrate that human UCB is a source of mesenchymal progenitors and may be used in cell transplantation and a wide range of gene-therapy treatments.

研究表明,骨髓中发现的基质细胞群可以扩增并分化为具有骨、软骨、肌肉、神经和脂肪细胞表型的细胞。然而,间充质干细胞(MSCs)是否存在于人脐带血(UCB)中一直是争论的主题。在这项研究中,我们报道了从人UCB单核部分提取的成纤维细胞样细胞群,这些细胞具有成骨和成脂肪的潜力,以及在连续培养中维持超过6个月的细胞亚群的存在。这些细胞表达CD29、CD44、CD90、CD95、CD105、CD166和MHC类,但不表达CD14、CD34、CD40、CD45、CD80、CD86、CD117、CD152或MHC II类。我们还比较了使用携带绿色荧光蛋白的慢体病毒和腺病毒载体将基因转移到来自UCB的间充质干细胞后的基因表达,因为将靶基因转移到间充质干细胞需要可靠的基因传递系统,这已经成为系统递送治疗基因的潜在平台。慢病毒载体比腺病毒载体更有效地转导这些细胞,并且我们将转基因表达维持了至少5周。这是首次报道显示ucb衍生的MSCs可以通过慢病毒载体表达外源基因。这些结果表明,人UCB是间充质祖细胞的来源,可用于细胞移植和广泛的基因治疗。
{"title":"Characterization and gene transfer in mesenchymal stem cells derived from human umbilical-cord blood","authors":"Fei-Zhou Lu ,&nbsp;Masayuki Fujino ,&nbsp;Yusuke Kitazawa ,&nbsp;Taro Uyama ,&nbsp;Yuko Hara ,&nbsp;Naoko Funeshima ,&nbsp;Jian-Yuan Jiang ,&nbsp;Akihiro Umezawa ,&nbsp;Xiao-Kang Li","doi":"10.1016/j.lab.2005.07.003","DOIUrl":"10.1016/j.lab.2005.07.003","url":null,"abstract":"<div><p>It has been shown that the stromal-cell population found in bone marrow can be expanded and differentiated into cells with the phenotypes of bone, cartilage, muscle, neural, and fat cells. However, whether mesenchymal stem cells (MSCs) are present in human umbilical-cord blood (UCB) has been the subject of ongoing debate. In this study, we report on a population of fibroblastlike cells derived from the mononuclear fraction of human UCB with osteogenic and adipogenic potential, as well as the presence of a subset of cells that have been maintained in continuous culture for more than 6 months. These cells were found to express CD29, CD44, CD90, CD95, CD105, CD166, and MHC class, but not CD14, CD34, CD40, CD45, CD80, CD86, CD117, CD152, or MHC class II. We also compared gene expression after gene transfer using lenti- and adenoviral vectors carrying the green fluorescence protein to the MSCs derived from UCB because a reliable gene-delivery system is required to transfer target genes into MSCs, which have attracted attention as potential platforms for the systemic delivery of therapeutic genes. The lentiviral vectors can transduce these cells more efficiently than can adenoviral vectors, and we maintained transgene expression for at least 5 weeks. This is the first report showing that UCB-derived MSCs can express exogenous genes by way of a lentivirus vector. These results demonstrate that human UCB is a source of mesenchymal progenitors and may be used in cell transplantation and a wide range of gene-therapy treatments.</p></div>","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"146 5","pages":"Pages 271-278"},"PeriodicalIF":0.0,"publicationDate":"2005-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.07.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25663737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 51
Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice 四硫钼酸盐对阿霉素对小鼠心脏损伤的保护作用
Pub Date : 2005-11-01 DOI: 10.1016/j.lab.2005.07.004
Guoqing Hou , Robert Dick , Gerald D. Abrams , George J. Brewer

Cardiac toxicity is the limiting factor in therapy with doxorubicin, an otherwise useful cancer drug. In this article we detail our study of a mouse model of doxorubicin-induced cardiac toxicity in which, after 4 days’ treatment, doxorubicin caused marked increases in plasma concentrations of creatine kinase, lactic dehydrogenase, and troponin I, indicators of cardiac injury; marked increases in the plasma concentrations of tumor necrosis factor-α and interleukin-1β, both inflammatory cytokines; and a marked increase in the plasma concentration of interleukin-2, an indicator of cytotoxic T-cell activation. Therapy with tetrathiomolybdate, designed to limit copper availability, eliminated almost all of the increases of these six parameters in plasma. The marked protection against cardiac injury by doxorubicin in tetrathiomolybdate-treated animals suggests that tetrathiomolybdate would be of use clinically in helping prevent doxorubicin toxicity in patients. In other preclinical work, it has been shown that tetrathiomolybdate potentiates the chemotherapeutic effect of doxorubicin in cancer, so a double benefit might accrue clinically from the combined use of tetrathiomolybdate and doxorubicin. The mechanism by which tetrathiomolybdate protects against doxorubicin toxicity is of considerable interest. Our working hypothesis, based on the inhibition of interleukin-2 by tetrathiomolybdate as shown here, is that tetrathiomolybdate interrupts the inflammatory cascade at the activated–T-lymphocyte stage.

心脏毒性是阿霉素治疗的限制因素,阿霉素是一种有用的抗癌药物。在这篇文章中,我们详细介绍了我们对阿霉素诱导心脏毒性小鼠模型的研究,在治疗4天后,阿霉素引起心肌损伤指标肌酸激酶、乳酸脱氢酶和肌钙蛋白I的血浆浓度显著升高;肿瘤坏死因子-α和白细胞介素-1β两种炎症细胞因子血浆浓度显著升高;血浆白细胞介素-2浓度显著升高,白细胞介素-2是细胞毒性t细胞活化的指标。用四硫钼酸盐治疗,旨在限制铜的可用性,消除了血浆中这六个参数的几乎所有增加。阿霉素对经四硫钼酸盐处理的动物心脏损伤有明显的保护作用,提示四硫钼酸盐可用于临床预防阿霉素对患者的毒性。在其他临床前研究中,已经证明四硫钼酸盐增强了阿霉素对癌症的化疗效果,因此四硫钼酸盐和阿霉素联合使用可能会在临床上产生双重效益。四硫钼酸盐对阿霉素毒性的保护机制引起了相当大的兴趣。基于四硫钼酸盐对白细胞介素-2的抑制作用,我们的工作假设是,四硫钼酸盐在激活t淋巴细胞阶段阻断了炎症级联反应。
{"title":"Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice","authors":"Guoqing Hou ,&nbsp;Robert Dick ,&nbsp;Gerald D. Abrams ,&nbsp;George J. Brewer","doi":"10.1016/j.lab.2005.07.004","DOIUrl":"10.1016/j.lab.2005.07.004","url":null,"abstract":"<div><p>Cardiac toxicity is the limiting factor in therapy with doxorubicin, an otherwise useful cancer drug. In this article we detail our study of a mouse model of doxorubicin-induced cardiac toxicity in which, after 4 days’ treatment, doxorubicin caused marked increases in plasma concentrations of creatine kinase, lactic dehydrogenase, and troponin I, indicators of cardiac injury; marked increases in the plasma concentrations of tumor necrosis factor-α and interleukin-1<sub>β</sub>, both inflammatory cytokines; and a marked increase in the plasma concentration of interleukin-2, an indicator of cytotoxic T-cell activation. Therapy with tetrathiomolybdate, designed to limit copper availability, eliminated almost all of the increases of these six parameters in plasma. The marked protection against cardiac injury by doxorubicin in tetrathiomolybdate-treated animals suggests that tetrathiomolybdate would be of use clinically in helping prevent doxorubicin toxicity in patients. In other preclinical work, it has been shown that tetrathiomolybdate potentiates the chemotherapeutic effect of doxorubicin in cancer, so a double benefit might accrue clinically from the combined use of tetrathiomolybdate and doxorubicin. The mechanism by which tetrathiomolybdate protects against doxorubicin toxicity is of considerable interest. Our working hypothesis, based on the inhibition of interleukin-2 by tetrathiomolybdate as shown here, is that tetrathiomolybdate interrupts the inflammatory cascade at the activated–T-lymphocyte stage.</p></div>","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"146 5","pages":"Pages 299-303"},"PeriodicalIF":0.0,"publicationDate":"2005-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.07.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25650611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 44
Levosimendan improves postresuscitation outcomes in a rat model of CPR 左西孟旦改善大鼠心肺复苏模型的复苏后结果
Pub Date : 2005-11-01 DOI: 10.1016/j.lab.2005.07.005
Lei Huang , Max Harry Weil , Shijie Sun , Gianluca Cammarata , Lan Cao , Wanchun Tang

In this study we sought to determine whether a calcium sensitizer, levosimendan, would have a more favorable effect on postresuscitation myocardial function and, consequently, postresuscitation survival than β-adrenergic dobutamine. The extreme decrease in survival before hospital discharge of resuscitated victims is attributed, in part, to postresuscitation myocardial failure, and dobutamine has been recommended for the management of postresuscitation myocardial failure. We studied a total of 15 animals. Ventricular fibrillation was induced in Sprague-Dawley rats weighing 450 to 550 g. Cardiopulmonary resuscitation (CPR), including chest compressions and mechanical ventilation, was begun after 8 minutes of untreated cardiac arrest. Electrical defibrillation was attempted after 6 minutes of CPR. Each animal was resuscitated. Animals were randomized to undergo treatment with levosimendan, dobutamine, or saline-solution placebo. These agents were administered 10 minutes after the return of spontaneous circulation. Levosimendan was administered in a loading dose of 12 μg kg−1 over a 10-minute period, followed by infusion of 0.3 μg kg−1 min−1 over the next 230 minutes. Dobutamine was continuously infused at a dosage of 3 μg kg−1 min−1. Saline-solution placebo was administered in the same volume and over the same amount of time as levosimendan. Levosimendan and dobutamine produced comparable increases in cardiac output and rate of left-ventricular pressure increase. However, administration of levosimendan resulted in lower heart rates and lesser increases in left ventricular diastolic pressure compared with both dobutamine and placebo. The duration of postresuscitation survival was significantly greater with levosimendan (16±2 hours), intermediate with dobutamine (11±2 hours) and least with saline-solution placebo (8±1 hour). Levosimendan and dobutamine both improved postresuscitation myocardial function. However, levosimendan produced more favorable postresuscitation myocardial function and increased the duration of postresuscitation survival.

在这项研究中,我们试图确定钙增敏剂左西孟旦是否比β-肾上腺素能多巴酚丁胺对复苏后心肌功能和复苏后生存率有更有利的影响。复苏患者出院前生存率的急剧下降部分归因于复苏后心肌衰竭,多巴酚丁胺已被推荐用于复苏后心肌衰竭的管理。我们总共研究了15只动物。体重450 ~ 550 g的Sprague-Dawley大鼠心室颤动。心肺复苏(CPR),包括胸部按压和机械通气,在未经治疗的心脏骤停8分钟后开始。心肺复苏术6分钟后尝试电除颤。每只动物都苏醒了。动物随机接受左西孟旦、多巴酚丁胺或盐水溶液安慰剂治疗。这些药物在自然循环恢复后10分钟给药。左西孟旦以12 μg kg−1的负荷剂量在10分钟内给药,然后在接下来的230分钟内输注0.3 μg kg−1 min−1。以3 μg kg−1 min−1的剂量持续输注多巴酚丁胺。盐溶液安慰剂与左西孟旦以相同的体积和相同的时间给予。左西孟旦和多巴酚丁胺在心输出量和左心室压升高率方面产生了相当的增加。然而,与多巴酚丁胺和安慰剂相比,左西孟旦的使用导致较低的心率和较小的左心室舒张压升高。左西孟旦组复苏后生存时间显著延长(16±2小时),多巴酚丁胺组居中(11±2小时),盐水溶液安慰剂组最短(8±1小时)。左西孟旦和多巴酚丁胺均可改善复苏后心肌功能。然而,左西孟旦复苏后心肌功能更有利,复苏后生存时间延长。
{"title":"Levosimendan improves postresuscitation outcomes in a rat model of CPR","authors":"Lei Huang ,&nbsp;Max Harry Weil ,&nbsp;Shijie Sun ,&nbsp;Gianluca Cammarata ,&nbsp;Lan Cao ,&nbsp;Wanchun Tang","doi":"10.1016/j.lab.2005.07.005","DOIUrl":"10.1016/j.lab.2005.07.005","url":null,"abstract":"<div><p>In this study we sought to determine whether a calcium sensitizer, levosimendan, would have a more favorable effect on postresuscitation myocardial function and, consequently, postresuscitation survival than β-adrenergic dobutamine. The extreme decrease in survival before hospital discharge of resuscitated victims is attributed, in part, to postresuscitation myocardial failure, and dobutamine has been recommended for the management of postresuscitation myocardial failure. We studied a total of 15 animals. Ventricular fibrillation was induced in Sprague-Dawley rats weighing 450 to 550 g. Cardiopulmonary resuscitation (CPR), including chest compressions and mechanical ventilation, was begun after 8 minutes of untreated cardiac arrest. Electrical defibrillation was attempted after 6 minutes of CPR. Each animal was resuscitated. Animals were randomized to undergo treatment with levosimendan, dobutamine, or saline-solution placebo. These agents were administered 10 minutes after the return of spontaneous circulation. Levosimendan was administered in a loading dose of 12 μg kg<sup>−1</sup> over a 10-minute period, followed by infusion of 0.3 μg kg<sup>−1</sup> min<sup>−1</sup> over the next 230 minutes. Dobutamine was continuously infused at a dosage of 3 μg kg<sup>−1</sup> min<sup>−1</sup>. Saline-solution placebo was administered in the same volume and over the same amount of time as levosimendan. Levosimendan and dobutamine produced comparable increases in cardiac output and rate of left-ventricular pressure increase. However, administration of levosimendan resulted in lower heart rates and lesser increases in left ventricular diastolic pressure compared with both dobutamine and placebo. The duration of postresuscitation survival was significantly greater with levosimendan (16±2 hours), intermediate with dobutamine (11±2 hours) and least with saline-solution placebo (8±1 hour). Levosimendan and dobutamine both improved postresuscitation myocardial function. However, levosimendan produced more favorable postresuscitation myocardial function and increased the duration of postresuscitation survival.</p></div>","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"146 5","pages":"Pages 256-261"},"PeriodicalIF":0.0,"publicationDate":"2005-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.07.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25663735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 57
Heterogeneity of cag genotypes and clinical outcome of Helicobacter pylori infection 幽门螺杆菌感染cag基因型的异质性及临床转归
Pub Date : 2005-11-01 DOI: 10.1016/j.lab.2005.06.010
Michele Sozzi , Maria Luisa Tomasini , Carla Vindigni , Stefania Zanussi , Rosamaria Tedeschi , Giancarlo Basaglia , Natale Figura , Paolo De Paoli

Helicobacter pylori infecting strains may include colony subtypes with different cytotoxin-associated gene (cag) genotypes. We sought to determine whether the cag heterogeneity of infecting strains is related to the clinical outcome of infection. Gastric biopsies for culture and histologic study were taken from 19 patients infected with cagA-positive strains (6 with duodenal ulcer, 8 with atrophic gastritis, and 5 with nonatrophic gastritis). For each biopsy, DNA was extracted from 10 single colonies and from a sweep of colonies. Polymerase chain reaction (PCR) for cagA and cagE (both located in the right half of cag) and virB11 (located in the left half of cag) was performed. Random amplified polymorphic DNA PCR (RAPD-PCR) and sequencing of glmM PCR product were performed to verify strain identity of colonies with different cag genotypes. In all patients, PCR from sweeps were positive for cagA, showing that all specimens contained cagA-positive H. pylori subtypes. In 11 patients, PCR products from all colonies were positive for cagA, cagE, and virB11, but in 8 patients, PCR products from varying numbers of colonies were negative for 1 or more cag genes. RAPD-PCR and sequencing of glmM PCR product confirmed the strain identities of colonies with different cag genotypes. We detected cag deletions in 6 of 8, 2 of 5, and 0 of 6 patients with atrophic gastritis, nonatrophic gastritis, and duodenal ulcer, respectively (P = .02). In conclusion, changes in cag genotype in single colony isolates from subjects infected with cagA-positive H. pylori strains are more common in atrophic than in nonatrophic gastritis or duodenal ulcer. These findings are consistent with host-induced (acid secretion?) adaptive changes in cag genotype during infection.

幽门螺杆菌感染菌株可能包括具有不同细胞毒素相关基因(cag)基因型的菌落亚型。我们试图确定感染菌株的cag异质性是否与感染的临床结果有关。对19例caga阳性菌株感染患者(十二指肠溃疡6例,萎缩性胃炎8例,非萎缩性胃炎5例)行胃活检培养及组织学研究。对于每次活检,从10个单个菌落和扫描菌落中提取DNA。对cagA和cagE(均位于cag的右半部分)以及virB11(位于cag的左半部分)进行聚合酶链反应(PCR)。采用随机扩增多态性DNA PCR (RAPD-PCR)和glmM PCR产物测序,验证不同cag基因型菌落的菌株同一性。在所有患者中,PCR扫描cagA阳性,表明所有标本都含有cagA阳性的幽门螺杆菌亚型。在11例患者中,来自所有菌落的PCR产物均为cagA、cagE和virB11阳性,但在8例患者中,来自不同数量菌落的PCR产物均为1个或多个cag基因阴性。RAPD-PCR和glmM PCR产物测序证实了不同cag基因型菌落的菌株身份。萎缩性胃炎、非萎缩性胃炎和十二指肠溃疡患者8例中有6例,5例中有2例,6例中有0例检测到cag缺失(P = 0.02)。综上所述,从感染caga阳性幽门螺杆菌的个体中分离出的单菌落cag基因型变化在萎缩性胃炎或十二指肠溃疡中比在非萎缩性胃炎或十二指肠溃疡中更常见。这些发现与感染期间宿主诱导的(酸分泌?)cag基因型适应性变化一致。
{"title":"Heterogeneity of cag genotypes and clinical outcome of Helicobacter pylori infection","authors":"Michele Sozzi ,&nbsp;Maria Luisa Tomasini ,&nbsp;Carla Vindigni ,&nbsp;Stefania Zanussi ,&nbsp;Rosamaria Tedeschi ,&nbsp;Giancarlo Basaglia ,&nbsp;Natale Figura ,&nbsp;Paolo De Paoli","doi":"10.1016/j.lab.2005.06.010","DOIUrl":"10.1016/j.lab.2005.06.010","url":null,"abstract":"<div><p><em>Helicobacter pylori</em> infecting strains may include colony subtypes with different cytotoxin-associated gene (<em>cag</em>) genotypes. We sought to determine whether the <em>cag</em> heterogeneity of infecting strains is related to the clinical outcome of infection. Gastric biopsies for culture and histologic study were taken from 19 patients infected with <em>cagA</em>-positive strains (6 with duodenal ulcer, 8 with atrophic gastritis, and 5 with nonatrophic gastritis). For each biopsy, DNA was extracted from 10 single colonies and from a sweep of colonies. Polymerase chain reaction (PCR) for <em>cagA</em> and <em>cagE</em> (both located in the right half of <em>cag</em>) and <em>virB11</em> (located in the left half of <em>cag</em>) was performed. Random amplified polymorphic DNA PCR (RAPD-PCR) and sequencing of <em>glmM</em> PCR product were performed to verify strain identity of colonies with different <em>cag</em> genotypes. In all patients, PCR from sweeps were positive for <em>cagA</em>, showing that all specimens contained <em>cagA</em>-positive <em>H. pylori</em> subtypes. In 11 patients, PCR products from all colonies were positive for <em>cagA</em>, <em>cagE</em>, and <em>virB11</em>, but in 8 patients, PCR products from varying numbers of colonies were negative for 1 or more <em>cag</em> genes. RAPD-PCR and sequencing of <em>glmM</em> PCR product confirmed the strain identities of colonies with different <em>cag</em> genotypes. We detected <em>cag</em> deletions in 6 of 8, 2 of 5, and 0 of 6 patients with atrophic gastritis, nonatrophic gastritis, and duodenal ulcer, respectively (<em>P</em> = .02). In conclusion, changes in <em>cag</em> genotype in single colony isolates from subjects infected with <em>cagA</em>-positive <em>H. pylori</em> strains are more common in atrophic than in nonatrophic gastritis or duodenal ulcer. These findings are consistent with host-induced (acid secretion?) adaptive changes in <em>cag</em> genotype during infection.</p></div>","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"146 5","pages":"Pages 262-270"},"PeriodicalIF":0.0,"publicationDate":"2005-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.06.010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25663736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 39
Information for readers 读者资讯
Pub Date : 2005-11-01 DOI: 10.1016/S0022-2143(05)00338-0
{"title":"Information for readers","authors":"","doi":"10.1016/S0022-2143(05)00338-0","DOIUrl":"https://doi.org/10.1016/S0022-2143(05)00338-0","url":null,"abstract":"","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"146 5","pages":"Page CO3"},"PeriodicalIF":0.0,"publicationDate":"2005-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0022-2143(05)00338-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136908081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
This month in J Lab Clin Med 本月在J Lab临床医学杂志上
Pub Date : 2005-11-01 DOI: 10.1016/j.lab.2005.09.002
Dale E. Hammerschmidt MD (Editor-in-Chief)
{"title":"This month in J Lab Clin Med","authors":"Dale E. Hammerschmidt MD (Editor-in-Chief)","doi":"10.1016/j.lab.2005.09.002","DOIUrl":"https://doi.org/10.1016/j.lab.2005.09.002","url":null,"abstract":"","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"146 5","pages":"Pages 253-255"},"PeriodicalIF":0.0,"publicationDate":"2005-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.09.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136908075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
About the cover illustration 关于封面插图
Pub Date : 2005-11-01 DOI: 10.1016/j.lab.2005.09.003
Dale E. Hammerschmidt MD (Editor-in-Chief)
{"title":"About the cover illustration","authors":"Dale E. Hammerschmidt MD (Editor-in-Chief)","doi":"10.1016/j.lab.2005.09.003","DOIUrl":"10.1016/j.lab.2005.09.003","url":null,"abstract":"","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"146 5","pages":"Pages 306-307"},"PeriodicalIF":0.0,"publicationDate":"2005-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.09.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25650613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Serum complement factor I decreases Staphylococcus aureus phagocytosis 血清补体因子I降低金黄色葡萄球菌的吞噬作用
Pub Date : 2005-11-01 DOI: 10.1016/j.lab.2005.07.001
Kenji M. Cunnion, E. Stephen Buescher, Pamela S. Hair

Complement-mediated opsonization of Staphylococcus aureus is a critical host defense in animal models. Specifically, C3b and CD35 play important roles in effective opsonophagocytosis of S. aureus. We have shown that complement control protein factor I mediates cleavage of the complement opsonin C3b bound to the S. aureus surface. In this study, we examined the physiologic relevance of this observation by determining whether factor I-mediated cleavage of S. aureus-bound C3b decreased phagocytosis of S. aureus by neutrophils. Compared with controls, anti-factor I antibody inhibited C3b-cleavage on the S. aureus surface by >83% (as measured by iC3b generation) and increased phagocytosis of S. aureus by >100%. Treatment of C3b-coated S. aureus with factor I increased generation of iC3b (75%), decreased the total amount of C3-fragments bound to the S. aureus surface (58%), and decreased the number of bacteria phagocytosed (40%). Testing specifically for C3-fragments shed from the S. aureus surface, we found that factor I increased shedding (43%). Notably, these factor I-mediated effects were of the same magnitude regardless of whether factor H, a known cofactor for factor I, was present. These findings indicate that S. aureus benefits from, and possibly manipulates, the normally host-protective activity of factor I cleavage of C3b, which results in bacterial escape from complement-mediated opsonophagocytosis. Because escaping opsonophagocytosis-mediated destruction is a necessary mechanism for bacterial survival resulting in human disease, preventing cleavage of C3b on the S. aureus surface, and thereby enhancing opsonophagocytosis, is a promising potential target for therapeutic intervention.

在动物模型中,补体介导的金黄色葡萄球菌的调理是一个关键的宿主防御。具体来说,C3b和CD35在金黄色葡萄球菌的有效调理吞噬作用中起重要作用。我们已经证明,补体控制蛋白因子I介导了与金黄色葡萄球菌表面结合的补体调理蛋白C3b的裂解。在这项研究中,我们通过确定因子i介导的金黄色葡萄球菌结合C3b的裂解是否会减少中性粒细胞对金黄色葡萄球菌的吞噬,来检验这一观察结果的生理学相关性。与对照组相比,抗因子I抗体抑制金黄色葡萄球菌表面c3b的裂解率为83%(以iC3b代计),使金黄色葡萄球菌的吞噬率增加了100%。用因子I处理c3b包被的金黄色葡萄球菌,增加了iC3b的生成(75%),减少了与金黄色葡萄球菌表面结合的c3片段总数(58%),减少了被吞噬的细菌数量(40%)。对金黄色葡萄球菌表面脱落的c3片段进行特异性检测,我们发现因子1增加脱落(43%)。值得注意的是,无论因子H(已知因子I的辅助因子)是否存在,这些因子I介导的影响都具有相同的幅度。这些发现表明,金黄色葡萄球菌受益于并可能操纵C3b的因子I切割的正常宿主保护活性,这导致细菌逃避补体介导的调理吞噬作用。由于逃避调理自噬细胞介导的破坏是细菌生存导致人类疾病的必要机制,因此防止金黄色葡萄球菌表面C3b的裂解,从而增强调理自噬细胞作用,是一个有希望的潜在治疗干预靶点。
{"title":"Serum complement factor I decreases Staphylococcus aureus phagocytosis","authors":"Kenji M. Cunnion,&nbsp;E. Stephen Buescher,&nbsp;Pamela S. Hair","doi":"10.1016/j.lab.2005.07.001","DOIUrl":"10.1016/j.lab.2005.07.001","url":null,"abstract":"<div><p>Complement-mediated opsonization of <em>Staphylococcus aureus</em> is a critical host defense in animal models. Specifically, C3b and CD35 play important roles in effective opsonophagocytosis of <em>S. aureus</em>. We have shown that complement control protein factor I mediates cleavage of the complement opsonin C3b bound to the <em>S. aureus</em> surface. In this study, we examined the physiologic relevance of this observation by determining whether factor I-mediated cleavage of <em>S. aureus</em>-bound C3b decreased phagocytosis of <em>S. aureus</em> by neutrophils. Compared with controls, anti-factor I antibody inhibited C3b-cleavage on the <em>S. aureus</em> surface by &gt;83% (as measured by iC3b generation) and increased phagocytosis of <em>S. aureus</em> by &gt;100%. Treatment of C3b-coated <em>S. aureus</em> with factor I increased generation of iC3b (75%), decreased the total amount of C3-fragments bound to the <em>S. aureus</em> surface (58%), and decreased the number of bacteria phagocytosed (40%). Testing specifically for C3-fragments shed from the <em>S. aureus</em> surface, we found that factor I increased shedding (43%). Notably, these factor I-mediated effects were of the same magnitude regardless of whether factor H, a known cofactor for factor I, was present. These findings indicate that <em>S. aureus</em> benefits from, and possibly manipulates, the normally host-protective activity of factor I cleavage of C3b, which results in bacterial escape from complement-mediated opsonophagocytosis. Because escaping opsonophagocytosis-mediated destruction is a necessary mechanism for bacterial survival resulting in human disease, preventing cleavage of C3b on the <em>S. aureus</em> surface, and thereby enhancing opsonophagocytosis, is a promising potential target for therapeutic intervention.</p></div>","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"146 5","pages":"Pages 279-286"},"PeriodicalIF":0.0,"publicationDate":"2005-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.07.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25663738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 22
Effects of recombinant-hemoglobin solutions rHb2.0 and rHb1.1 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock 重组血红蛋白溶液rHb2.0和rHb1.1对失血性休克大鼠血压、肠血流量和肠道氧合的影响
Pub Date : 2005-11-01 DOI: 10.1016/j.lab.2005.07.011
N.J.H. Raat
{"title":"Effects of recombinant-hemoglobin solutions rHb2.0 and rHb1.1 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock","authors":"N.J.H. Raat","doi":"10.1016/j.lab.2005.07.011","DOIUrl":"10.1016/j.lab.2005.07.011","url":null,"abstract":"","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"146 5","pages":"Pages 304-305"},"PeriodicalIF":0.0,"publicationDate":"2005-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.07.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25650612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
C-reactive protein increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells c反应蛋白增加基质金属蛋白酶-2在培养的人血管平滑肌细胞中的表达和活性
Pub Date : 2005-11-01 DOI: 10.1016/j.lab.2005.07.010
Gabriella Doronzo, Isabella Russo, Luigi Mattiello, Mariella Trovati, Giovanni Anfossi

The C-reactive protein (CRP) is a strong predictor of cardiovascular events both in the general population and in patients with coronary artery disease. We aimed to evaluate whether in cultured human vascular smooth muscle cells (hVSMC) CRP modulates the synthesis and release of metalloproteinase-2 (MMP-2), which is deeply involved in plaque instabilization and vascular remodeling, and of the tissue inhibitor of metalloproteinase-2 (TIMP-2). Both in supernatants and in cell lysates of cultured hVSMC exposed to CRP (0–10 mg/L), we evaluated MMP-2 activity (gelatin zymography), MMP-2 and TIMP-2 protein synthesis (immunoblotting), MMP-2 and TIMP-2 mRNA expression (reverse transcription-polymerase chain reaction). CRP effects were also investigated after cell exposure to specific MEK inhibitor PD98059 (15–30 μmol/L) to evaluate the involvement of mitogen-activated protein kinase (MAPK). CRP upregulated MMP-2 mRNA expression. MMP-2 synthesis and activity were increased by 1–10 mg/L CRP starting from 8-hour incubation. The effect was prevented by exposure to PD98059. CRP did not modify TIMP-2 mRNA expression, protein synthesis, and secretion. CRP, at concentrations that predict cardiovascular events, upregulates MMP-2 mRNA expression and increases MMP-2 protein synthesis and release in hVSMC through mechanisms involving activation of MAPK pathway. These data indicate that CRP is not only a risk marker for vascular events, but it is also directly involved in the mechanisms leading to remodeling and instabilization of atherosclerotic plaque.

c反应蛋白(CRP)是普通人群和冠状动脉疾病患者心血管事件的一个强有力的预测因子。我们的目的是评估在培养的人血管平滑肌细胞(hVSMC)中,CRP是否调节金属蛋白酶2 (MMP-2)的合成和释放,金属蛋白酶2 (MMP-2)深入参与斑块不稳定和血管重塑,以及金属蛋白酶2的组织抑制剂(TIMP-2)。在培养的hVSMC暴露于CRP (0-10 mg/L)的上清液和细胞裂解液中,我们评估了MMP-2活性(明胶酶谱法)、MMP-2和TIMP-2蛋白合成(免疫印迹法)、MMP-2和TIMP-2 mRNA表达(逆转录聚合酶链反应)。研究了细胞暴露于MEK特异性抑制剂PD98059 (15-30 μmol/L)后CRP的影响,以评估有丝分裂原活化蛋白激酶(MAPK)的影响。CRP上调MMP-2 mRNA表达。从8小时孵育开始,1-10 mg/L CRP增加MMP-2的合成和活性。暴露在PD98059中可以防止这种效应。CRP不改变TIMP-2 mRNA表达、蛋白合成和分泌。在预测心血管事件的浓度下,CRP通过激活MAPK通路的机制上调hVSMC中MMP-2 mRNA的表达并增加MMP-2蛋白的合成和释放。这些数据表明,CRP不仅是血管事件的风险标志物,而且还直接参与导致动脉粥样硬化斑块重塑和不稳定的机制。
{"title":"C-reactive protein increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells","authors":"Gabriella Doronzo,&nbsp;Isabella Russo,&nbsp;Luigi Mattiello,&nbsp;Mariella Trovati,&nbsp;Giovanni Anfossi","doi":"10.1016/j.lab.2005.07.010","DOIUrl":"10.1016/j.lab.2005.07.010","url":null,"abstract":"<div><p>The C-reactive protein (CRP) is a strong predictor of cardiovascular events both in the general population and in patients with coronary artery disease. We aimed to evaluate whether in cultured human vascular smooth muscle cells (hVSMC) CRP modulates the synthesis and release of metalloproteinase-2 (MMP-2), which is deeply involved in plaque instabilization and vascular remodeling, and of the tissue inhibitor of metalloproteinase-2 (TIMP-2). Both in supernatants and in cell lysates of cultured hVSMC exposed to CRP (0–10 mg/L), we evaluated MMP-2 activity (gelatin zymography), MMP-2 and TIMP-2 protein synthesis (immunoblotting), MMP-2 and TIMP-2 mRNA expression (reverse transcription-polymerase chain reaction). CRP effects were also investigated after cell exposure to specific MEK inhibitor PD98059 (15–30 μmol/L) to evaluate the involvement of mitogen-activated protein kinase (MAPK). CRP upregulated MMP-2 mRNA expression. MMP-2 synthesis and activity were increased by 1–10 mg/L CRP starting from 8-hour incubation. The effect was prevented by exposure to PD98059. CRP did not modify TIMP-2 mRNA expression, protein synthesis, and secretion. CRP, at concentrations that predict cardiovascular events, upregulates MMP-2 mRNA expression and increases MMP-2 protein synthesis and release in hVSMC through mechanisms involving activation of MAPK pathway. These data indicate that CRP is not only a risk marker for vascular events, but it is also directly involved in the mechanisms leading to remodeling and instabilization of atherosclerotic plaque.</p></div>","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"146 5","pages":"Pages 287-298"},"PeriodicalIF":0.0,"publicationDate":"2005-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.07.010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25650610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 40
期刊
Journal of Laboratory and Clinical Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1